PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-18 pm EDT
48.58 USD   -1.40%
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Response in Real Life
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Trachoma Elimination - Millions More to Benefit From Donated Azithromycin

06/29/2022 | 05:06am EDT

The World Health Organization (WHO) today welcomed the announcement by Pfizer Inc. that it will extend its donation of the antibiotic Zithromax® (azithromycin) for trachoma elimination until 2030, building on the company's 23-year commitment to fight the world's leading infectious cause of blindness.

Caused by repeated bacterial infection of the eyes, trachoma blinds the poorest people in the world. WHO recommends a four-part strategy to eliminate trachoma as a public health problem. This strategy takes the acronym "SAFE", representing: surgery for advanced disease, antibiotics to clear infection, and facial cleanliness and environmental improvement (particularly increased access to water and sanitation) to reduce transmission. Pfizer's Zithromax® donation is a critical part of SAFE, and is managed by the International Trachoma Initiative at the Task Force for Global Health, Decatur (GA), USA, an organization in official relations with WHO.

"Continuing the donation programme will bring relief to millions of people around the world who are affected by this preventable neglected tropical disease," said Dr Ren Minghui, WHO's Assistant Director-General for Universal Health Coverage/Communicable and Noncommunicable Diseases. "WHO is very grateful for Pfizer's ongoing commitment to helping prevent trachomatous blindness."

Caroline Roan, Senior Vice-President Global Health & Patient Impact, Pfizer Inc., commented, "Trachoma is a debilitating disease that should no longer wreak havoc on people's lives and livelihoods. We are proud to support our longstanding trachoma partners working tirelessly towards elimination and improving lives worldwide."

Between 2002 and 2021, due to a combination of SAFE strategy implementation, improved living conditions and better data, the estimated number of people living in trachoma-endemic areas worldwide fell 91% from 1517 million to 136 million. But over the past 2 years, the coronavirus disease (COVID-19) pandemic has limited the activity of programmes against neglected tropical diseases in many countries. Community-based work, such as antibiotic mass drug administration for trachoma, has been particularly adversely affected.

In the road map for neglected tropical diseases 2021-2030, endorsed by the World Health Assembly in November 2020, trachoma is targeted for global elimination as a public health problem by 2030. To date, 13 countries (Cambodia, China, the Islamic Republic of Iran, the Lao People's Democratic Republic, the Gambia, Ghana, Mexico, Morocco, Myanmar, Nepal, Oman, Saudi Arabia and Togo) have been validated as having achieved this milestone.

Copyright World Health Organization. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about PFIZER, INC.
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Resp..
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
08/17GSK Says First US Plaintiff to Drop Zantac Case
DJ
08/16Plaintiff in first Zantac lawsuit set for trial drops case
RE
08/16Ambrx Biopharma Names Kate Hermans Interim CEO
MT
08/16PFIZER : Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVI..
PU
08/16Pfizer Inc. - Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive ..
AQ
08/16Digital innovations and congress coverage led to an increase in all hub users
AQ
08/15Pfizer CEO tests positive for COVID-19, has mild symptoms
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,62x
Yield 2022 3,34%
Capitalization 273 B 273 B -
EV / Sales 2022 2,57x
EV / Sales 2023 3,25x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 48,58 $
Average target price 56,53 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-17.73%276 521
JOHNSON & JOHNSON-2.51%440 598
ELI LILLY AND COMPANY14.66%301 034
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.35%250 080
NOVO NORDISK A/S5.17%239 447